TUC WEEKLY INTELLIGENCE BRIEF - September 14, 2026
THE UPLYFT COLLECTIVE
Weekly Intelligence Brief, Week of September 14, 2026
The Signal
This week’s question is who pays to prove it.
On Thursday, FDA convenes a public workshop on testosterone use in menopausal women: an area of substantial off-label use, no FDA-approved product indicated for women in the United States, and unresolved questions about efficacy beyond sexual desire disorder and about long-term safety. The agency is asking what evidence exists and what is missing. The harder question, the one that explains decades of absence, is who could ever afford to generate it.
The same question is shaping biotech exits and clinical AI. When an evidence base is expensive to build, someone must have both the incentive and the ability to fund it. When regulators do less of the screening, someone else inherits the burden of proof. When that owner is unclear, the evidence gap becomes the market gap.
What Smart Money Is Watching: clinical questions that remain unanswered not only because they are scientifically difficult, but because the economics of generating the answer remain unresolved.
The Capital Tape
The reverse merger stopped being plan B.
Roughly two dozen biotech reverse mergers have been announced so far in 2026, more than double the ten announced across all of 2025, according to a list compiled by life sciences advisory firm JB Strategy Partners. One recent example is Ambros Therapeutics, a pain drugmaker that in late August announced plans to combine with the struggling Werewolf Therapeutics alongside a $150 million private placement.
The word used behind closed doors is shell. The more presentable term is vehicle. Both describe a public company that derives much of its value simply from being public. What changed is the perception: these were historically read as last-ditch deals between two desperate parties, and they are now a considered choice. Carlos Ramirez, a partner at Cooley, told BioPharma Dive that the IPO will always be the gold standard for going public, but reverse mergers are being discussed, and not as the plan B or C. Demand has risen far enough that advisers are questioning whether there are enough quality shells to meet it.
The detail that matters most is about board behavior. Ramirez reports that private biotech boards are now asking to prepare for an IPO, a reverse merger, and a SPAC at once, in order to keep their options open. That is not indecision. It is a recognition that the best route is unknowable until the moment you need it, and that credible preparation on all three is what preserves the right to choose on your own timing.
Board question: what must be true, financially, operationally, and in investor readiness, for us to pursue any of the three within the next twelve months?
The money behind the movement is concentrating.
RA Capital Management participated in four biotech financings in September alone, including a $225 million Series A for Solstice Oncology and a $55 million Series A for immune system specialist Tectora Therapeutics, after co-leading a $56 million round for Typewriter Therapeutics and joining a group backing metabolic disease company Superluminal Medicines. BioPharma Dive’s own tally puts twenty drug developers public in 2026, five of them this month, against eleven in all of last year, with fourteen raising more than $250 million.
When a handful of crossover funds are this active across both reverse merger financings and Series A rounds, they are not merely deploying capital. They are shaping what a fundable company looks like.
Board question: who appears repeatedly in the deals adjacent to ours, and what do those companies have in common?
Sources: BioPharma Dive on the reverse merger surge, September 10 · BioPharma Dive, This Week in Charts, September 11 · Fierce Biotech on Ambros and Werewolf
The Regulatory Inflection
An evidence gap with a commercial architecture problem.
On Thursday, September 17, FDA holds a hybrid public workshop on testosterone use in menopausal women. The agency says the meeting will examine current scientific evidence and critical knowledge gaps to inform future research and potential drug development. The related docket, FDA-2026-N-5479, accepts comments through 11:59 p.m. ET on October 19. In-person registration has closed. Virtual registration remains open.
Start with what FDA itself says. Approved testosterone products are indicated for men with low testosterone associated with a medical condition. There is no FDA-approved testosterone product indicated for menopausal women in the United States. In practice, women who receive testosterone here are generally treated off-label with male-labeled formulations at lower doses, or through compounded preparations.
The evidence is real but bounded. A meta-analysis of 36 randomized trials involving 8,480 women found testosterone therapy improved sexual function in postmenopausal women with hypoactive sexual desire disorder, including roughly one additional satisfying sexual event per month on average versus placebo. The international consensus position is clear that HSDD is the only evidence-based indication, and that evidence remains insufficient for cognition, musculoskeletal health, other symptoms, or disease prevention. Long-term safety evidence, particularly on cardiovascular and breast cancer risk, remains limited. Those are precisely the gaps FDA has put on the agenda. Members should go into Thursday clear-eyed: advocates on both sides overstate, and anyone who walks into a board meeting claiming the science here is settled will be wrong.
Why the evidence was never generated is the more useful question. Cost and duration are part of it. So is a specific scientific obstacle: aromatization, the conversion of testosterone to estrogen in tissues including the breast, has been linked to increased breast cancer risk and has long constrained clinical development. And so is commercial architecture. Definitive long-duration safety programs are expensive, and the ability to fund one depends on whether a sponsor can capture enough value from the result to justify the burden. Where the asset, the indication, and the return are hard to protect, that math has often failed. That is not the only explanation, and it would be wrong to reduce decades of regulatory history to a single cause. But it is a major structural reason, and it is the one least discussed.
Nobody runs the definitive trial if nobody can own the answer.
Which is why one January development is worth watching. Aviva Bio announced on January 26 that it received formal FDA feedback in a Type B meeting on requirements for developing a testosterone therapy for women. Its candidate, AVA-291 (d3-T), is a deuterium-substituted testosterone designed to retain androgen activity while resisting aromatization. In that feedback, FDA acknowledged the potential breast cancer risk associated with testosterone use in women, the central safety issue that has historically limited development. Aviva also reported data accepted for AACR in April showing AVA-291 with roughly 1,000-fold less potential to stimulate breast cancer cell proliferation than ordinary testosterone. This does not resolve the science, and a Type B meeting is development feedback rather than endorsement. It matters as an illustration: a differentiated, potentially protectable asset is what can make a rigorous program financeable, and it is aimed squarely at the safety question that stalled the field.
The TUC position. The asymmetry between what is approved for men and what is available to women is difficult to defend as a process outcome. The remedy is not to lower the evidentiary bar. It is to address the structure that has kept the evidence from being generated: a sponsor with a differentiated asset so a definitive program has an owner, non-dilutive funding through foundations and federal research dollars where commercial incentives cannot reach, and an indication framed broadly enough to justify the cost. Approving a product on thin data would not serve women. Leaving several million women to source an unapproved dose of a male-labeled product does not serve them either.
The docket is open through October 19 and comments are read. If you are a clinician who prescribes off-label, a researcher who has run these studies, or an executive who has watched a women’s health program die on commercial math, your comment speaks directly to what FDA says it is examining. Personal experience is not clinical evidence, but it can help the agency understand real-world use, unmet need, and the practical consequences of the current gap.
Worth noting for anyone tracking federal comment windows: FDA’s separate docket on generative AI-enabled medical devices, FDA-2026-N-7874, closes on the same date. October 19 is a single deadline covering two questions the agency has put to the field.
Sources: FDA workshop page and docket details · FDA on approved testosterone products · Global consensus statement, 36-trial meta-analysis · Aviva Bio announcement, January 26, 2026 · FDA generative AI docket
Career, Board & Capital
Career: the capability gaining value is making a women’s health indication financeable.
Across women’s health there are clinical questions that go unanswered in part because no one has assembled a case capable of funding the answer. Building that case means reading a molecule’s protectability, an indication’s addressable population, a payer’s evidence threshold, and a regulator’s safety expectation at once, then putting together a sponsor, a funder, and a trial design that survive all four.
Very few people can do that, and they are frequently the reason some categories get built while others stay theoretical. If you can make a women’s health indication financeable, you are not a subject matter expert. You are the reason the program exists. Make the claim in those terms: not “I work in women’s health,” but “I built the commercial and regulatory case that made a women’s health program fundable, and I know which assumptions break it.”
Board: put evidence ownership on the agenda.
For every major claim your product depends on, ask who is funding the study that proves it and whether the company can capture value from the result. A program whose key evidence nobody has a clear incentive to generate carries a risk that rarely appears on a slide until it is too late to address.
Capital: ask the protectability question before the market size question.
Standard diligence starts with market size. This week argues for one step earlier. Ask whether the company has a credible path to capturing value from the answer its market depends on. An off-patent molecule with a compelling clinical story can be a meaningful public health opportunity while remaining a difficult venture investment, and the two are frequently conflated in women’s health, where enthusiasm for unmet need can substitute for analysis of who captures the value of meeting it.
The corollary points to where opportunity sits. Reformulation, novel delivery, isotopic substitution, device-drug combinations, and new composition-of-matter approaches to established molecules are how a hard-to-own answer becomes an ownable one. Where generic status has slowed evidence generation for decades, differentiation is often what unlocks the trial, the approval, the coverage, and the market.
Diligence question: what does this company own, and is it the thing the market actually pays for?
What Boards Are Quietly Discussing
If the definitive study our category needs has never been run, is that a scientific gap or a financing gap?
The distinction changes the response. A scientific gap calls for better research design. A financing gap calls for a different sponsor, a different funding source, or a differentiated asset. Boards that misdiagnose the second as the first can spend years waiting for evidence that no party has a clear reason to produce.
The Syndicate Desk
Biweekly diligence sessions are underway again this month.
Two places to look from this week’s tape. First, companies whose core asset is a differentiated, protectable position in a category with real clinical demand and no approved product. That combination is rarer than it sounds, and it is where long-standing unmet need can convert quickly. Second, private companies with a credible path to the public markets whose boards have prepared more than one route, since optionality on exit structure is becoming a marker of governance quality.
Send what you are seeing to hello@theuplyftcollective.com: company name, stage, raise size, one sentence on why the return case could be real, and one sentence on why you trust the founder, category, evidence, or timing. Nothing shared constitutes a commitment, and confidential information should not be circulated without permission.
The Uplyft Lens: Three Moves for This Month
1. Thursday, September 17: attend the workshop, or send someone.
Virtual registration is open. A federal agency is publicly examining why a category serving millions of women has no approved product. Whatever your view of the evidence, that room is worth being in, and the docket stays open through October 19 either way.
2. This week: ask who can capture value from the evidence your business depends on.
Take your most important unproven claim, clinical, commercial, or operational, and identify who has both the incentive and the ability to fund the study that settles it. If the answer is unclear, you have found a structural risk rather than a research gap, and it needs a structural fix.
3. Before your next board meeting: put all three go-public paths on the agenda.
IPO, reverse merger, SPAC. Not to choose, but to be ready to choose. In a changing market, credible optionality is what preserves timing.
The most valuable question in women’s health may not be what is the unmet need. It may be who can afford to prove the answer.
The Uplyft Collective is a private leadership ecosystem for architects of strategy in healthcare, pharma, biotech, medtech, and life sciences. Take your seat at the table.
